MedTrace Logo

Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal

NCT00529620 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1833

Last updated 2010-05-27

No results posted yet for this study

Summary

The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria in children. Children aged 2 months to 5 years will be randomized to receive IPT with one of three regimens during the transmission season: sulfadoxine-pyrimethamine (SP) plus amodiaquine, show to be highly effective for IPT in a recent trial; SP plus piperaquine, used for malaria prophylaxis in China for many years; or Duocotexcin (a combination of piperaquine with an artemisinin).

Conditions

Interventions

DRUG

sulfalene-pyrimethamine plus amodiaquine

Monthly treatments during the malaria transmission season

DRUG

dihydroartemisinin plus piperaquine

Monthly treatments during the transmission season

DRUG

sulfadoxine pyrimethamine plus piperaquine

Monthly treatments during the malaria transmission season

Sponsors & Collaborators

  • Cheikh Anta Diop University, Senegal

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Badara Cisse, PhD · Universite Cheikh Anta Diop

  • Paul J Milligan, PhD · London School of Hygiene and Tropical Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Senegal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00529620 on ClinicalTrials.gov